Literature DB >> 23136616

Accuracy of (99m)Tc-sestamibi scintimammography for breast cancer diagnosis.

Sonia Marta Moriguchi1, Laurival Antônio DE Luca, Beatriz Lotufo Griva, Kátia Hiromoto Koga, Eduardo Tinois DA Silva, Heloisa DE Luca Vespoli, Gilberto Uemura.   

Abstract

Scintimammography using (99m)Tc-sestamibi is a noninvasive and painless diagnostic imaging method that is used to detect breast cancer when mammography is inconclusive. Because of the advantages of labeling with (99m)Tc-sestamibi and its high efficiency in detecting carcinomas, it is the most widespread agent for this purpose. Its accumulation in the tumor has multifactorial causes and does not depend on the presence of architectural distortion or local or diffuse density variation in the breast. The objective of this study was to evaluate the accuracy of scintimammography for detecting breast cancer. One hundred and fifty-seven patients presenting 158 palpable and non-palpable breast nodules were evaluated. Three patients were male and 154 were female, aged between 14 and 81 years. All patients underwent scintimammography, and the nodule was subjected to cytological or histological study, i.e., the gold standard for diagnosing cancer. One hundred and eleven malignant and 47 benign nodules were detected, with predominance of ductal carcinomas (n=94) and fibroadenoma/fibrocystic condition (n=11/n=11), respectively. The mean size was 3.11 cm (7-10 cm) among the malignant nodules and 2.07 cm among the benign nodules (0.5-10 cm). The sensitivity, specificity, positive predictive value, negative predictive value and accuracy were 89, 89, 95, 78 and 89%, respectively. Analysis on the histological types showed that the technique was more effective on tumors that were more aggressive, such as ductal carcinoma. In this study, (99m)Tc-sestamibi scintimammography was shown to be an important tool for diagnosing breast cancer when mammography was inconclusive.

Entities:  

Year:  2010        PMID: 23136616      PMCID: PMC3490387          DOI: 10.3892/etm_00000033

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  50 in total

1.  Chest wall recurrence of breast cancer detected by scintimammography.

Authors:  J C Kuhn; A Siegel; S Poplack; B Arrick
Journal:  Clin Nucl Med       Date:  2000-02       Impact factor: 7.794

Review 2.  A meta-analysis of scintimammography: an evidence-based approach to its clinical utility.

Authors:  Rahain Hussain; John R Buscombe
Journal:  Nucl Med Commun       Date:  2006-07       Impact factor: 1.690

3.  Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial.

Authors:  H Palmedo; H J Biersack; S Lastoria; J Maublant; E Prats; H E Stegner; P Bourgeois; R Hustinx; A J Hilson; A Bischof-Delaloye
Journal:  Eur J Nucl Med       Date:  1998-04

4.  Factors influencing false negative rates in xeromammography.

Authors:  L Kalisher
Journal:  Radiology       Date:  1979-11       Impact factor: 11.105

Review 5.  The role of (99m)Tc methoxyisobutylisonitrile in imaging breast cancer.

Authors:  A D Waxman
Journal:  Semin Nucl Med       Date:  1997-01       Impact factor: 4.446

Review 6.  The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis.

Authors:  R Taillefer
Journal:  Semin Nucl Med       Date:  1999-01       Impact factor: 4.446

7.  Delayed diagnosis of breast cancer as a result of normal mammograms.

Authors:  B D Mann; A E Giuliano; L W Bassett; M S Barber; W Hallauer; D L Morton
Journal:  Arch Surg       Date:  1983-01

Review 8.  Evaluation of a palpable breast mass.

Authors:  W L Donegan
Journal:  N Engl J Med       Date:  1992-09-24       Impact factor: 91.245

9.  Occult breast cancer presenting with axillary metastases. Updated management.

Authors:  P L Baron; M P Moore; D W Kinne; F C Candela; M P Osborne; J A Petrek
Journal:  Arch Surg       Date:  1990-02

10.  Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement.

Authors:  R Taillefer; A Robidoux; R Lambert; S Turpin; J Laperrière
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.